The company’s revenue from operations in Q4FY26 was down 12% to Rs 7,516 crore versus Rs 8,506 crore in the corresponding quarter of the previous financial year.
The company’s board recommended a final dividend of Rs 8 per equity share for the financial year 2025-26, subject to approval of shareholders at the ensuing Annual General Meeting. The company has set the record date for determining eligible shareholders on July 10, 2026.
The profit after tax (PAT) was down 81% on a sequential basis from Rs 1,190 crore in Q3FY26 while topline declined 14% quarter-on-quarter from Rs 8,727 crore in the October-December quarter of FY26.
However, revenue increased 3% for the full year ended March 31, 2026 to Rs 33,593 crore from Rs 32,553 crore in the year ago period.
Growth was broad-based across key markets, except for North America which declined primarily on account of lower Lenalidomide sales and a one-time Shelf Stock Adjustment (SSA) of Rs 450 crore related to the product. Favourable foreign exchange rate movements further supported overall growth.
Excluding the one-time SSA, consolidated revenues were at Rs 7,970 crore billion in Q4FY26, a decline of 6.3% YoY and 8.7% QoQ and Rs 34,050 crore in FY26, a growth of 4.6% YoY.Gross Margin for Q4FY26 at 44.8%, a decline of 1,074 basis points (bps) YoY and 881 bps QoQ. For FY26 it stood at 52.8%, a decline of 573 bps YoY.
The YoY decline for the quarter was primarily on account of reduced sales of Lenalidomide, price erosion in North America and Europe Generics and a one-time SSA impact indicated earlier. FY26 was further impacted by one-time new Labour Code related provision in Q3FY26.
Excluding the one-offs related to SSA and new Labour Codes, gross margin for Q4FY26 at 48% and FY26 at 53.5%.
